Setting

Asia Pacific Antibiotics Market 2020-2030 by Drug Class, Action Mechanism, Drug Origin, Activity Spectrum, Route of Administration, Drug Type, and Country: Trend Forecast and Growth Opportunity

Published: 26 Aug 2020 | Report Code: 10247652 | Pages: 121

Asia Pacific antibiotics market will grow by 4.1% annually with a total addressable market cap of $253.1 billion over 2020-2030 owing to the rising incidences of bacterial infection, growing awareness and need for new drugs and treatment amid the COVID-19 epidemic. Highlighted with 32 tables and 58 figures, this 121-page report “Asia Pacific Antibiotics Market 2020-2030 by Drug Class, Action Mechanism, Drug Origin, Activity Spectrum, Route of Administration, Drug Type, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Asia Pacific antibiotics market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2030 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.) In-depth qualitative analyses include identification and investigation of the following aspects: • Market Structure • Growth Drivers • Restraints and Challenges • Emerging Product Trends & Market Opportunities • Porter’s Fiver Forces The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Asia Pacific antibiotics market in every aspect of the classification from perspectives of Drug Class, Action Mechanism, Drug Origin, Activity Spectrum, Route of Administration, Drug Type, and Country. Based on Drug Class, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Cephalosporin • Penicillin • Macrolides • Fluoroquinolones • Quinolones • Monobactam • Aminoglycosides • Carbapenem • Other Drug Classes Based on Action Mechanism, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Cell Wall Synthesis Inhibitors • Mycolic Acid Inhibitors • RNA Synthesis Inhibitors • DNA Synthesis Inhibitors • Protein Synthesis Inhibitors • Other Mechanisms Based on Drug Origin, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Natural Antibiotics • Semi-synthetic Antibiotics • Synthetic Antibiotics Based on Activity Spectrum, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Broad-spectrum Antibiotics • Narrow-spectrum Antibiotics Based on Route of Administration, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Oral Administration • Intravenous Administration • Other Administration Routes Based on Drug Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Brand Antibiotics • Generic Antibiotics Geographically, the following national/local markets are fully investigated: • Japan • China • South Korea • Australia • India • Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, and Sri Lanka) For each country, detailed analysis and data for annual revenue are available for 2019-2030. The breakdown of key national markets by Drug Class, Drug Origin, and Route of Administration over the forecast years are also included. The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players. Specifically, potential risks associated with investing in Asia Pacific antibiotics market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions. Key Players (this may not be a complete list and extra companies can be added upon request): Abbott Laboratories Astellas Pharma AstraZeneca Plc Bayer AG Bristol Myers Squibb Company Cipla Inc. Dr. Reddy’s Laboratories Ltd. Eli Lilly and Company F. Hoffmann-La Roche Ltd. Gilead Sciences, Inc. GlaxoSmithKline plc. Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals) Mayne Pharma Group Ltd. MELINTA THERAPEUTICS, INC. Merck KGaA Novartis AG Pfizer Inc. Sanofi Sun Pharmaceutical Industries Ltd. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

Table Of Contents

1 Introduction	7
1.1 Industry Definition and Research Scope	7
1.1.1 Industry Definition	7
1.1.2 Research Scope	8
1.2 Research Methodology	11
1.2.1 Overview of Market Research Methodology	11
1.2.2 Market Assumption	12
1.2.3 Secondary Data	12
1.2.4 Primary Data	12
1.2.5 Data Filtration and Model Design	14
1.2.6 Market Size/Share Estimation	15
1.2.7 Research Limitations	16
1.3 Executive Summary	17
2 Market Overview and Dynamics	20
2.1 Market Size and Forecast	20
2.1.1 Impact of COVID-19 on the Market	21
2.2 Major Growth Drivers	23
2.3 Market Restraints and Challenges	27
2.4 Emerging Opportunities and Market Trends	30
2.5 Porter’s Fiver Forces Analysis	34
3 Segmentation of Asia Pacific Market by Drug Class	38
3.1 Market Overview by Drug Class	38
3.2 Cephalosporin	40
3.3 Penicillin	41
3.4 Macrolides	42
3.5 Fluoroquinolones	43
3.6 Quinolones	44
3.7 Monobactam	45
3.8 Aminoglycosides	46
3.9 Carbapenem	47
3.10 Other Drug Classes	48
4 Segmentation of Asia Pacific Market by Action Mechanism	49
4.1 Market Overview by Action Mechanism	49
4.2 Cell Wall Synthesis Inhibitors	51
4.3 Mycolic Acid Inhibitors	52
4.4 RNA Synthesis Inhibitors	53
4.5 DNA Synthesis Inhibitors	54
4.6 Protein Synthesis Inhibitors	55
4.7 Other Mechanisms	56
5 Segmentation of Asia Pacific Market by Drug Origin	57
5.1 Market Overview by Drug Origin	57
5.2 Natural Antibiotics	59
5.3 Semi-synthetic Antibiotics	60
5.4 Synthetic Antibiotics	61
6 Segmentation of Asia Pacific Market by Activity Spectrum	62
6.1 Market Overview by Activity Spectrum	62
6.2 Broad-spectrum Antibiotics	64
6.3 Narrow-spectrum Antibiotics	65
7 Segmentation of Asia Pacific Market by Route of Administration	66
7.1 Market Overview by Route of Administration	66
7.2 Oral Administration	68
7.3 Intravenous Administration	69
7.4 Other Administration Routes	70
8 Segmentation of Asia Pacific Market by Drug Type	71
8.1 Market Overview by Drug Type	71
8.2 Brand Antibiotics	73
8.3 Generic Antibiotics	74
9 Asia-Pacific Market 2019-2030 by Country	75
9.1 Overview of Asia-Pacific Market	75
9.2 Japan	78
9.3 China	81
9.4 Australia	83
9.5 India	85
9.6 South Korea	87
9.7 Rest of APAC Region	89
10 Competitive Landscape	91
10.1 Overview of Key Vendors	91
10.2 New Product Launch, Partnership, Investment, and M&A	94
10.3 Company Profiles	95
Abbott Laboratories	95
Astellas Pharma	97
AstraZeneca Plc	98
Bayer AG	99
Bristol Myers Squibb Company	100
Cipla Inc.	101
Dr. Reddy’s Laboratories Ltd.	102
Eli Lilly and Company	103
F. Hoffmann-La Roche Ltd.	104
Gilead Sciences, Inc.	105
GlaxoSmithKline plc.	106
Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals)	107
Mayne Pharma Group Ltd.	108
MELINTA THERAPEUTICS, INC.	109
Merck KGaA	110
Novartis AG	111
Pfizer Inc.	112
Sanofi	113
Sun Pharmaceutical Industries Ltd.	114
11 Investing in Asia Pacific Market: Risk Assessment and Management	115
11.1 Risk Evaluation of Asia Pacific Market	115
11.2 Critical Success Factors (CSFs)	118
Related Reports and Products	121
List Of Tables

Table 1.  Snapshot of Asia Pacific Antibiotics Market, 2019-2030	18
Table 2.  Main Product Trends and Market Opportunities in Asia Pacific Antibiotics Market	30
Table 3. Asia Pacific Antibiotics Market by Drug Class, 2019-2030, $ mn	38
Table 4. Asia Pacific Antibiotics Market by Action Mechanism, 2019-2030, $ mn	49
Table 5. Asia Pacific Antibiotics Market by Drug Origin, 2019-2030, $ mn	57
Table 6. Asia Pacific Antibiotics Market by Activity Spectrum, 2019-2030, $ mn	62
Table 7. Asia Pacific Antibiotics Market by Route of Administration, 2019-2030, $ mn	66
Table 8. Asia Pacific Antibiotics Market by Drug Type, 2019-2030, $ bn	71
Table 9. APAC Antibiotics Market by Country, 2019-2030, $ bn	76
Table 10. Japan Antibiotics Market by Drug Class, 2019-2030, $ mn	80
Table 11. Japan Antibiotics Market by Drug Origin, 2019-2030, $ mn	80
Table 12. Japan Antibiotics Market by Route of Administration, 2019-2030, $ mn	80
Table 13. China Antibiotics Market by Drug Class, 2019-2030, $ mn	82
Table 14. China Antibiotics Market by Drug Origin, 2019-2030, $ mn	82
Table 15. China Antibiotics Market by Route of Administration, 2019-2030, $ mn	82
Table 16. Australia Antibiotics Market by Drug Class, 2019-2030, $ mn	84
Table 17. Australia Antibiotics Market by Drug Origin, 2019-2030, $ mn	84
Table 18. Australia Antibiotics Market by Route of Administration, 2019-2030, $ mn	84
Table 19. India Antibiotics Market by Drug Class, 2019-2030, $ mn	86
Table 20. India Antibiotics Market by Drug Origin, 2019-2030, $ mn	86
Table 21. India Antibiotics Market by Route of Administration, 2019-2030, $ mn	86
Table 22. South Korea Antibiotics Market by Drug Class, 2019-2030, $ mn	88
Table 23. South Korea Antibiotics Market by Drug Origin, 2019-2030, $ mn	88
Table 24. South Korea Antibiotics Market by Route of Administration, 2019-2030, $ mn	88
Table 25. Antibiotics Market in Rest of APAC by Country, 2019-2030, $ bn	90
Table 26. Abbott Laboratories: Company Snapshot	95
Table 27. Abbott Laboratories: Business Segmentation	95
Table 28. Abbott Laboratories: Product Portfolio	96
Table 29. Abbott Laboratories: Revenue, 2016-2018, $ mn	96
Table 30. Abbott Laboratories: Recent Developments	96
Table 31.  Risk Evaluation for Investing in Asia Pacific Market, 2019-2030	116
Table 32. Critical Success Factors and Key Takeaways	119
List Of Figures

Figure 1. Research Method Flow Chart	11
Figure 2. Breakdown of Primary Research	13
Figure 3. Bottom-up Approach and Top-down Approach for Market Estimation	15
Figure 4. Asia Pacific Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2030	17
Figure 5. Asia Pacific Antibiotics Market, 2019-2030, $ mn	20
Figure 6. Impact of COVID-19 on Business	21
Figure 7. Primary Drivers and Impact Factors of Asia Pacific Antibiotics Market	23
Figure 8. GDP per capita in the World, 1960-2018, $ thousand	26
Figure 9. Forecast of Middle-class Population by Region, 2015-2030, million	26
Figure 10. Primary Restraints and Impact Factors of Asia Pacific Antibiotics Market	27
Figure 11. Investment Opportunity Analysis	31
Figure 12. Porter’s Fiver Forces Analysis of Asia Pacific Antibiotics Market	34
Figure 13. Breakdown of Asia Pacific Antibiotics Market by Drug Class, 2019-2030, % of Revenue	39
Figure 14. Asia Pacific Addressable Market Cap in 2020-2030 by Drug Class, Value ($ mn) and Share (%)	39
Figure 15. Asia Pacific Antibiotics Market: Cephalosporin, 2019-2030, $ mn	40
Figure 16. Asia Pacific Antibiotics Market: Penicillin, 2019-2030, $ mn	41
Figure 17. Asia Pacific Antibiotics Market: Macrolides, 2019-2030, $ mn	42
Figure 18. Asia Pacific Antibiotics Market: Fluoroquinolones, 2019-2030, $ mn	43
Figure 19. Asia Pacific Antibiotics Market: Quinolones, 2019-2030, $ mn	44
Figure 20. Asia Pacific Antibiotics Market: Monobactam, 2019-2030, $ mn	45
Figure 21. Asia Pacific Antibiotics Market: Aminoglycosides, 2019-2030, $ mn	46
Figure 22. Asia Pacific Antibiotics Market: Carbapenem, 2019-2030, $ mn	47
Figure 23. Asia Pacific Antibiotics Market: Other Drug Classes, 2019-2030, $ mn	48
Figure 24. Breakdown of Asia Pacific Antibiotics Market by Action Mechanism, 2019-2030, % of Sales Revenue	50
Figure 25. Asia Pacific Addressable Market Cap in 2020-2030 by Action Mechanism, Value ($ mn) and Share (%)	50
Figure 26. Asia Pacific Antibiotics Market: Cell Wall Synthesis Inhibitors, 2019-2030, $ mn	51
Figure 27. Asia Pacific Antibiotics Market: Mycolic Acid Inhibitors, 2019-2030, $ mn	52
Figure 28. Asia Pacific Antibiotics Market: RNA Synthesis Inhibitors, 2019-2030, $ mn	53
Figure 29. Asia Pacific Antibiotics Market: DNA Synthesis Inhibitors, 2019-2030, $ mn	54
Figure 30. Asia Pacific Antibiotics Market: Protein Synthesis Inhibitors, 2019-2030, $ mn	55
Figure 31. Asia Pacific Antibiotics Market: Other Mechanisms, 2019-2030, $ mn	56
Figure 32. Breakdown of Asia Pacific Antibiotics Market by Drug Origin, 2019-2030, % of Sales Revenue	58
Figure 33. Asia Pacific Addressable Market Cap in 2020-2030 by Drug Origin, Value ($ mn) and Share (%)	58
Figure 34. Asia Pacific Antibiotics Market: Natural Antibiotics, 2019-2030, $ mn	59
Figure 35. Asia Pacific Antibiotics Market: Semi-synthetic Antibiotics, 2019-2030, $ mn	60
Figure 36. Asia Pacific Antibiotics Market: Synthetic Antibiotics, 2019-2030, $ mn	61
Figure 37. Breakdown of Asia Pacific Antibiotics Market by Activity Spectrum, 2019-2030, % of Revenue	63
Figure 38. Asia Pacific Addressable Market Cap in 2020-2030 by Activity Spectrum, Value ($ mn) and Share (%)	63
Figure 39. Asia Pacific Antibiotics Market: Broad-spectrum Antibiotics, 2019-2030, $ mn	64
Figure 40. Asia Pacific Antibiotics Market: Narrow-spectrum Antibiotics, 2019-2030, $ mn	65
Figure 41. Breakdown of Asia Pacific Antibiotics Market by Route of Administration, 2019-2030, % of Revenue	67
Figure 42. Asia Pacific Addressable Market Cap in 2020-2030 by Route of Administration, Value ($ mn) and Share (%)	67
Figure 43. Asia Pacific Antibiotics Market: Oral Administration, 2019-2030, $ mn	68
Figure 44. Asia Pacific Antibiotics Market: Intravenous Administration, 2019-2030, $ mn	69
Figure 45. Asia Pacific Antibiotics Market: Other Administration Routes, 2019-2030, $ mn	70
Figure 46. Breakdown of Asia Pacific Antibiotics Market by Drug Type, 2019-2030, % of Revenue	71
Figure 47. Asia Pacific Addressable Market Cap in 2020-2030 by Drug Type, Value ($ bn) and Share (%)	72
Figure 48. Asia Pacific Antibiotics Market: Brand Antibiotics, 2019-2030, $ bn	73
Figure 49. Asia Pacific Antibiotics Market: Generic Antibiotics, 2019-2030, $ bn	74
Figure 50. Breakdown of APAC Antibiotics Market by Country, 2019 and 2030, % of Revenue	76
Figure 51. Contribution to APAC 2020-2030 Cumulative Revenue by Country, Value ($ bn) and Share (%)	77
Figure 52.  Antibiotics Market in Japan, 2019-2030, $ bn	79
Figure 53.  Antibiotics Market in China, 2019-2030, $ bn	81
Figure 54.  Antibiotics Market in Australia, 2019-2030, $ bn	83
Figure 55.  Antibiotics Market in India, 2019-2030, $ bn	85
Figure 56.  Antibiotics Market in South Korea, 2019-2030, $ bn	87
Figure 57.  Antibiotics Market in Rest of APAC, 2019-2030, $ bn	89
Figure 58. Growth Stage of Asia Pacific Antibiotics Industry over the Forecast Period	91

Key Players (this may not be a complete list and extra companies can be added upon request): 
Abbott Laboratories	
Astellas Pharma	
AstraZeneca Plc	
Bayer AG	
Bristol Myers Squibb Company	
Cipla Inc.	
Dr. Reddy’s Laboratories Ltd.	
Eli Lilly and Company	
F. Hoffmann-La Roche Ltd.	
Gilead Sciences, Inc.	
GlaxoSmithKline plc.	
Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals)	
Mayne Pharma Group Ltd.	
MELINTA THERAPEUTICS, INC.	
Merck KGaA	
Novartis AG	
Pfizer Inc.	
Sanofi	
Sun Pharmaceutical Industries Ltd.